Eden Bio

Eden Bio, founded in London in 2022, operates at the intersection of synthetic biology and artificial intelligence, providing a specialized service for the biomanufacturing industry. The company was established by Dr. Christopher Reynolds (CEO), Dr. Rachel Shaw (COO), and Dr. Evgenia Markova (CSO). Dr. Reynolds brings a unique background in both machine learning and synthetic biology, having previously co-founded Better Dairy, a precision fermentation company, where he demonstrated the power of machine learning in improving protein yield. This experience directly informed the creation of Eden Bio, with the goal of applying this technological approach across the broader protein production landscape.

The core of Eden Bio's business is a proprietary machine learning platform designed to accelerate the genetic engineering of microorganisms. The company serves clients in the precision fermentation sector, a market forecasted to grow significantly, which includes businesses producing industrial enzymes, therapeutics, and alternative food proteins. Many of these companies face a critical challenge: achieving a high enough protein yield from their engineered microbes to make production commercially viable. Eden Bio addresses this by using its computational and wet-lab tools to rapidly screen vast combinations of possible genetic modifications to a client's microbial strains. This process identifies the optimal genetic edits needed to significantly boost protein yield, making the microbes more robust for industrial-scale fermentation.

The business model is business-to-business (B2B), offering strain optimization as a service. By improving protein yields, Eden Bio enables its customers to reduce production costs and accelerate their time to market. The platform is described as "protein agnostic," meaning it can be applied to any company aiming to increase the yield of a specific protein, opening up applications across diverse markets. In November 2022, Eden Bio secured £1 million in a seed funding round led by SynBioVen, with participation from other venture capital firms and angel investors, to expand its R&D capabilities and further develop its machine learning platform.

Keywords: protein yield optimization, machine learning, synthetic biology, precision fermentation, strain engineering, biomanufacturing, genetic modification, microbial engineering, wet-lab tools, computational biology, alternative proteins, industrial enzymes, sustainable food production, cell factory, genome editing, SynBioVen, Christopher Reynolds, Rachel Shaw, Evgenia Markova, Better Dairy